Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Alzheimer's disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3'-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.
Pubmed ID: 30643396
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Alzheimer''s Disease International (ADI) believes that the key to winning the fight against dementia lies in a unique combination of Global Solutions and local knowledge. As such, it works locally, by empowering Alzheimer associations to promote and offer care and support for people with dementia and their carers, while working globally to focus attention on dementia. Our board is composed of people from around the world, and our staff team is based in London. ADI is the international federation of Alzheimer associations around the world, in official relations with the World Health Organization. Each member is the Alzheimer association in their country who support people with dementia and their families. ADI''s vision is an improved quality of life for people with dementia and their families throughout the world. ADI runs the Alzheimer University, a series of practical workshops aimed at helping the staff and volunteers of Alzheimer associations build and strengthen their organisations. ADI holds an annual international conference which is the longest running international conference on dementia. The conference is a unique multi-disciplinary event which unites people with an interest in dementia from around the world. World Alzheimer''s Day, celebrated on September 21 each year, is an opportunity to raise global awareness about dementia and its impact on families and the important work of our members throughout the world. Medical research is also important, and some of ADI''s member Alzheimer associations actively support research in their own countries. More information about research can be found on the web sites of Alzheimer''s Association (USA), Alzheimer''s Society (UK), Alzheimer Society of Canada, or the association in your country. For the fourth year, the Fondation M��d��ric Alzheimer and ADI are running Alzheimer''s Awards for evidence-based psychosocial interventions for people with dementia and their carers.
View all literature mentions